ALS Association to Help Fund Study of New Anti-Inflammation Drug

 

ALS Association pic

ALS Association
Image: alsa.org

For more than two decades, David Bohn has served as the president of Preferred Utilities Manufacturing Corporation in Redding, CT. Outside of his professional life, David Bohn is a longtime supporter of community organizations in Redding, CT, and medical charities, such as the ALS Association.

The ALS Association, which combats amyotrophic lateral sclerosis (ALF), also known as Lou Gehrig’s disease, recently announced a joint funding venture with ALS Finding a Cure and the Northeast ALS Consortium, which will provide $1 million in grant funding for testing of a new anti-inflammatory drug, RNS60. It is hoped this drug will curb inflammation, which can quicken the spread of ALS.

ALS is not an inflammatory disease by nature, but research indicates that inflammation in the central nervous system can speed up the progress of the disease after onset. Consequently, researchers have begun investigating ways to decrease inflammation levels in order to slow the progress of the disease. Preliminary data indicates that RNS60 has the potential to accomplish this.

The trial will involve 142 participants with ALS, will last 24 weeks, and will consist of two study groups. One group will take RNS60 and another will take a placebo. Researchers will monitor inflammation levels in each group to see if the study drug reduces them, and also what effects lowered inflammation levels have on the disease’s progress.

Neurologists Ettore Beghi, MD, in Milan, Italy; Letizia Mazzini, MD, in Novara, Italy; and Sabrina Paganoni, MD, PhD, in Boston, Massachusetts, will serve as the clinical trial’s principal investigators.

ACS and CVS Funding Smoke-Free College Programs

 Smoke-Free College Programs pic

Smoke-Free College Programs
Image: cvshealth.com

David G. Bohn of Redding, CT, has worked for Preferred Utilities Manufacturing Corporation since 1987 and became the company’s president in 1995. A lifelong philanthropist, David G. Bohn supports many nonprofit organizations, including the American Cancer Society.

The American Cancer Society (ACS) recently announced a joint grant funding effort with the CVS Health Foundation to provide money to 20 different colleges and universities across the United States. The funding will help energize the Tobacco-Free Generation Campus Initiative (TFGCI), which is a program aimed at lobbying for smoke-free and tobacco-free campuses. All told, ACS and CVS Health Foundation plan to spend $3.6 million over the next three years.

The money is intended to help schools lobby for policies that remove smoke and tobacco from classrooms and workplaces on campus. Schools will also receive help with education and cessation programs.

The University of Pennsylvania is the first school to receive funding through this program. It hopes to become the first Ivy League school to attain a totally tobacco-free campus.